Abrdn Life Sciences Investors (HQL) Fundamental Analysis: Revenue, Earnings & Valuation

1.61 / 10

Underperform

Fundamental evaluation presents inadequate characteristics (1.6/10). Strengths encompass Gross profit margin (%) and Current liabilities / Total liabilities (%), but headwinds are noted in Rate of return on total assets (%) and Annualized return on total assets (%). This justifies defensive view.

Analysis Checks(3/8)

Gross profit margin (%)

Value47.52

Score2/3

Weight15.28%

1M Return1.53%

Current liabilities / Total liabilities (%)

Value53.35

Score2/3

Weight15.71%

1M Return1.58%

Basic earnings per share (YoY growth rate %)

Value-7.27

Score0/3

Weight4.75%

1M Return0.50%

Rate of return on total assets (%)

Value-9.58

Score1/3

Weight14.21%

1M Return1.48%

Total profit / EBIT (%)

Value100.00

Score2/3

Weight15.05%

1M Return1.52%

Annualized return on total assets (%)

Value-9.58

Score1/3

Weight14.21%

1M Return1.48%

Diluted earnings per share (YoY growth rate %)

Value39.79

Score0/3

Weight8.30%

1M Return0.88%

Operating revenue (YoY growth rate %)

Value74.94

Score1/3

Weight12.48%

1M Return1.29%

Is HQL undervalued or overvalued?

HQL scores 1.61/10 on fundamentals and holds a Premium valuation at present. Backed by its 17.59% ROE, 4415.74% net margin, 5.84 P/E ratio, 0.97 P/B ratio, and 0.00% earnings growth, these metrics solidify its Underperform investment rating.